Zacks: Brokerages Expect Supernus Pharmaceuticals Inc (SUPN) Will Announce Earnings of $0.31 Per Share
Wall Street brokerages expect Supernus Pharmaceuticals Inc (NASDAQ:SUPN) to announce earnings of $0.31 per share for the current quarter, according to Zacks Investment Research. Six analysts have made estimates for Supernus Pharmaceuticals’ earnings. The lowest EPS estimate is $0.21 and the highest is $0.44. Supernus Pharmaceuticals reported earnings per share of $0.44 during the same quarter last year, which would indicate a negative year-over-year growth rate of 29.5%. The company is expected to issue its next earnings results on Tuesday, February 26th.
According to Zacks, analysts expect that Supernus Pharmaceuticals will report full-year earnings of $1.87 per share for the current year, with EPS estimates ranging from $1.78 to $2.02. For the next financial year, analysts forecast that the firm will report earnings of $2.44 per share, with EPS estimates ranging from $2.10 to $2.89. Zacks’ EPS averages are a mean average based on a survey of analysts that follow Supernus Pharmaceuticals.
Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $0.52 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.43 by $0.09. Supernus Pharmaceuticals had a net margin of 25.89% and a return on equity of 30.30%. The company had revenue of $102.99 million for the quarter, compared to analysts’ expectations of $100.75 million. During the same quarter last year, the company posted $0.29 earnings per share. The firm’s quarterly revenue was up 28.1% on a year-over-year basis.
Shares of SUPN stock opened at $45.11 on Wednesday. Supernus Pharmaceuticals has a 12-month low of $34.90 and a 12-month high of $61.25. The company has a debt-to-equity ratio of 0.77, a quick ratio of 2.65 and a current ratio of 2.82. The company has a market capitalization of $2.36 billion, a P/E ratio of 35.80 and a beta of 0.92.
Several hedge funds have recently made changes to their positions in the company. BlackRock Inc. raised its position in shares of Supernus Pharmaceuticals by 4.1% during the 3rd quarter. BlackRock Inc. now owns 8,003,001 shares of the specialty pharmaceutical company’s stock valued at $402,951,000 after purchasing an additional 312,332 shares during the period. FMR LLC raised its position in shares of Supernus Pharmaceuticals by 151.9% during the 3rd quarter. FMR LLC now owns 2,371,321 shares of the specialty pharmaceutical company’s stock valued at $119,396,000 after purchasing an additional 1,430,021 shares during the period. Wells Fargo & Company MN raised its position in shares of Supernus Pharmaceuticals by 6.8% during the 2nd quarter. Wells Fargo & Company MN now owns 957,210 shares of the specialty pharmaceutical company’s stock valued at $57,290,000 after purchasing an additional 61,100 shares during the period. Renaissance Technologies LLC raised its position in shares of Supernus Pharmaceuticals by 191.3% during the 2nd quarter. Renaissance Technologies LLC now owns 884,690 shares of the specialty pharmaceutical company’s stock valued at $52,949,000 after purchasing an additional 580,990 shares during the period. Finally, Janus Henderson Group PLC raised its position in shares of Supernus Pharmaceuticals by 21.6% during the 2nd quarter. Janus Henderson Group PLC now owns 665,392 shares of the specialty pharmaceutical company’s stock valued at $39,824,000 after purchasing an additional 118,289 shares during the period. Hedge funds and other institutional investors own 98.30% of the company’s stock.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.
Featured Article: How to Use the New Google Finance Tool
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.